Cancer
Conditions
Keywords
Cancer, circulating tumor biomarkers, circulating tumor DNA, Circulating tumor Cell (CTC)
Brief summary
Exploratory study on blood-borne biological markers and their correlation with clinical and pathological characteristics.
Detailed description
Exploratory multi-cohort study including different types of cancer (different organs and/or different histological types). Each kind of blood-borne biological markers analyses corresponds to a cohort.
Interventions
BIOLOGICALBlood sampling
Up to 5 blood samplings can be performed at different time points
PROCEDURETumor sampling
One tumor sampling can be performed, if applicable
OTHERStool sampling
Up to 5 blood samplings can be performed at different time points
Sponsors
Institut Curie
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient with any tumoral disease (proven or suspected), of any type and stage 2. More than18 years old 3. Signed informed consent form Additional inclusion criteria if a tumor sample is needed: 4. Tumor considered as accessible by biopsy 5. Normal blood coagulation tests on the last blood analysis Non-inclusion Criteria: 1. Patient in detention or protected by the law 2. Patient who cannot comply with the study follow up for geographical, social or psychological reasons Additional non-inclusion criteria if a tumor sample is needed: 3. Anticoagulant or antiaggregant that cannot be interrupted for the biopsy 4. central-nervous system metastases only (unless a diagnostic or curative surgery is planned before the inclusion in the study)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of the analysis of different blood-borne tumor biomarkers | 18 months | Success rate of the tested detection techniques. The success rate of a given detection technique is calculated by the ratio detection success / number of screened patients . |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation with biological and clinical data | 18 months | Number of biological analysis results correlated to clinical data. Establishment of a proof of concept |
Countries
France
Outcome results
None listed